公开(公告)号：EP3328859A1

公开(公告)日：2018-06-06

申请号：EP16830925.0

申请日：2016-07-28

申请人： Medivir AB

发明人： AYESA, Susana ,  ERSMARK, Karolina ,  KALAYANOV, Gennadiy ,  LEIJONMARCK, Marie ,  SALVADOR ODEN, Lourdes ,  WESTERLIND, Hans ,  WÄHLING, Horst ,  BERTRAND, Megan ,  BROCHU, Christian ,  GHIRO, Elise ,  KUHN, Cyrille ,  STURINO, Claudio ,  BYLUND, Johan ,  SEHGELMEBLE, Fernando

IPC分类号： C07D471/04 ,  A61K31/4725 ,  C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D471/10 ,  C07D471/20

摘要： Compounds of Formula (I): (Formula I), wherein Z1 is NR1A, CHR1A or CR1BR1B; one of Z2 and Z3 is CH or CR1A', the other is N, CH or CR1A'; n is 0, 1 or 2; q is 0, 1 or 2; R1A, R1A', R1B, R2 and R3 are as defined herein, their use as inhibitors of RSV and related aspects.

公开(公告)号：EP3271371A1

公开(公告)日：2018-01-24

申请号：EP16759215.3

申请日：2016-03-02

申请人： MEDIVIR AB

发明人： KALAYANOV, Gennadiy ,  PINHO, Pedro ,  TARGETT-ADAMS, Paul ,  TORSSELL, Staffan

IPC分类号： C07H19/10 ,  A61K31/7072 ,  A61P31/14

CPC分类号： C07H19/10 ,  A61K31/407 ,  A61K31/4178 ,  A61K31/439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/513 ,  A61K31/7072 ,  A61K38/13 ,  A61K38/20 ,  A61K38/21 ,  A61K38/55 ,  A61K45/06 ,  A61P31/14 ,  A61K2300/00

摘要： Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir; or b) simeprevir and/or JNJ56914845; or c) an HCV protease inhibitor selected from paritaprevir or ABT493, and an NS5A inhibitor selected from ombitasvir or ABT-530; or d) alisporavir; or e) EDP-239; or f) odalasvir and/or sovaprevir; or g) grazoprevir and/or elbasvir.